核素标记的PD-1与PD-L1显像剂在肿瘤诊断中的研究进展

Research progress of radionuclide labeled imaging agents targeting PD-1 and PD-L1 in the diagnosis of tumors

程序性死亡蛋白-1(PD-1)及其配体(PD-L1)免疫检查点抑制剂是目前肿瘤免疫治疗的研究热点,在多种肿瘤中的治疗效果显著,但部分患者未见临床获益。检测PD-1与PD-L1的表达水平对预测免疫治疗反应尤为重要。以核素标记的单克隆抗体、基因工程抗体片段或多肽为显像剂的功能性显像方法,可以无创、可重复、特异性地对全身PD-1与PD-L1表达进行定位和定量检测,有助于肿瘤负荷的动态评估,为有可能获益患者的筛选提供帮助。

Blocking the programmed cell death protein-1 (PD-1)and its ligand (PD-L1)immune checkpoint axis is a research focus in the field of tumor immunotherapy with remarkable clinical success,but a substantial number of patients do not respond.So it is important to predict the immunotherapy response by evaluating the expression of PD-1 and PD-L1.In order to evaluate tumor load dynamically and stratify responders to PD-1 and PD-L1 inhibitors,a repetitive,noninvasive functional imaging technique,which based on radionuclide labeled imaging agents targeting PD-1 and PD-L1,is needed to locate and quantify the spatiotemporal expression profiles of PD-1 and PD-L1 specifically.